Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 19/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13299870 | 0.94 | ELANE (0.47) | ELANE | |
| SCHEMBL13299882 | 0.94 | ELANE (0.47) | ELANE | |
| SCHEMBL3255175 | 0.89 | ELANE (0.48) | ELANEHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL13299875 | 0.89 | ELANE (0.48) | ELANEHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL13299866 | 0.89 | ELANE (0.48) | ELANEHDAC3HDAC4HDAC1HDAC7 | |
| Hydrochloric Acid SCHEMBL3249814 | 0.88 | ELANE (0.47) | ELANEHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL13299864 | 0.86 | ELANE (0.45) | ELANEHDAC3HDAC1 | |
| SCHEMBL13299880 | 0.86 | ELANE (0.43) | ELANE | |
| SCHEMBL13814743 | 0.86 | ELANE (0.43) | ELANE | |
| SCHEMBL13814744 | 0.86 | ELANE (0.46) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156509-A1 | Tri-peptide Inhibitors of Serine Elastases | ACCUTHERA, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090156509-A1 | Tri-peptide Inhibitors of Serine Elastases | ACCUTHERA, INC. (US) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156509-A1 | Tri-peptide Inhibitors of Serine Elastases | SCTR, CTRC, SERPINB1 | ELANE 4/4885HDAC3 216/4885HDAC4 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.